SAN DIEGO, May 25, 2021 /PRNewswire/ -- Evofem Biosciences,
Inc., (NASDAQ: EVFM) today announced that its CEO Saundra
Pelletier will present at the 2021 LD Micro Invitational XI on
Tuesday, June 8, 2021 at 1:00 p.m. ET (10:00 a.m.
Pelletier will provide an update on the commercialization of
Evofem's hormone-free contraceptive Phexxi® (lactic acid, citric
acid and potassium bitartrate), the ongoing Phase 3
clinical trial evaluating EVO100 for the prevention of chlamydia
and gonorrhea in women, and other ongoing initiatives.
To pre-register for the presentation, please
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is a commercial-stage biopharmaceutical company
committed to developing and commercializing
innovative products to address unmet needs in women's sexual
and reproductive health, including hormone-free, woman-controlled
contraception and protection from certain sexually transmitted
infections (STIs). For more information, please visit
Phexxi® is a registered trademark of Evofem
Investor Relations Contact
Evofem Biosciences, Inc.
Mobile: (917) 673-5775
View original content to download
SOURCE Evofem Biosciences, Inc.